A decade after the start of the ShortHER trial, new data published in JAMA Oncology sheds light on how tumor-infiltrating lymphocytes (TILs) can guide treatment decisions in early ERBB2-positive (HER2+) breast cancer.
Led by Dr. Maria Vittoria Dieci and colleagues, this analysis shows that higher levels of TILs are independently associated with better distant disease-free and overall survival. Notably, patients with TILs ≥20% had comparable or even better 10-year outcomes with de-escalated chemotherapy and trastuzumab duration.
These findings suggest that TILs can serve as a biomarker to safely guide adjuvant treatment de-intensification in select HER2+ breast cancer patientsan important step toward personalized care.
Thank you to Dr. Maria Vittoria Dieci and the co-investigators for this impactful contribution to the field.
Read the full article here: https://lnkd.in/dAH_Hmpa
